Zepbound Employer + ICHRA Coverage Navigation: How to Get Tirzepatide Covered in 2026

What Zepbound Actually Costs Without Coverage

Retail list price matters because it sets the ceiling you are negotiating against. Eli Lilly priced Zepbound at approximately $1,059.87 per month at launch, reflecting four single-dose auto-injector pens. That figure appears in Lilly's own published wholesale acquisition cost data and has remained roughly stable through early 2026 [1].

Why List Price Is Not What Most Patients Pay

Pharmacy benefit managers negotiate rebates that can reduce the plan's net cost by 30 to 50 percent, but those savings do not always flow to the patient at the counter. Cash-pay patients face the full list price unless they use a manufacturer coupon or compounding pharmacy. Insured patients face a co-pay or co-insurance percentage applied to the plan's contracted rate, which varies widely [2].

The 340B and Specialty Pharmacy Factor

Patients treated at 340B-covered health centers may access tirzepatide at a substantially lower ceiling price set by the Health Resources and Services Administration. The 340B ceiling price is not publicly disclosed, but the program has historically reduced drug costs by 25 to 50 percent below average manufacturer price [3]. Ask your prescriber whether their institution participates in 340B.

How Employer Group Health Plans Cover Zepbound

Most large employer plans (50+ employees) self-insure under ERISA, which means the employer, not an insurer, decides whether to include GLP-1 receptor agonists on the formulary [4]. Coverage decisions vary enormously.

Formulary Tiers and Prior Authorization

When an employer plan does cover Zepbound, it typically lands on Tier 3 or Tier 4 of the formulary, carrying co-insurance of 20 to 40 percent after meeting a deductible. Nearly every plan that covers GLP-1 agents requires prior authorization (PA). Standard PA criteria mirror FDA label language: a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia [5].

The FDA label for Zepbound specifies these exact thresholds [1]. Submitting a PA request that quotes label language directly tends to reduce back-and-forth with the plan's medical director.

Step Therapy Requirements

A significant share of employer plans impose step therapy, requiring documentation of a prior trial with a lower-cost agent. Orlistat (120 mg three times daily with meals) is the most commonly required step agent because it has been on the market since 1999 and carries a low wholesale cost. Some plans accept a 90-day behavioral intervention program in lieu of pharmacotherapy. Document every step in the chart before submitting the PA [6].

What to Include in a Strong PA Submission

A complete PA packet for Zepbound should contain:

• Current BMI and weight with date of measurement
• Qualifying comorbidity diagnosis codes (ICD-10: E66.01 for morbid obesity, E11.x for T2D)
• Documentation of a structured diet-and-exercise program lasting at least 12 weeks
• Step therapy completion records or a clinical exception statement
• Relevant labs (HbA1c, fasting glucose, lipid panel) dated within 90 days

The American Association of Clinical Endocrinology's 2023 Obesity Clinical Practice Guidelines recommend pharmacotherapy as a standard adjunct to lifestyle intervention when BMI criteria are met, which provides a guideline anchor for PA letters [7].

ICHRA and Zepbound: How Individual Coverage HRAs Work

An Individual Coverage HRA (ICHRA) is an employer-funded account that reimburses employees for individual health insurance premiums and, in some configurations, qualified medical expenses. The IRS finalized ICHRA rules in 2019, and they took full effect in 2020 [8].

Using ICHRA Funds for a Plan That Covers Zepbound

The core ICHRA strategy for Zepbound access involves three steps. First, the employee selects an individual market plan (on or off the ACA exchange) that includes Zepbound on its formulary. Second, the employer's ICHRA reimburses the premium for that plan. Third, the employee's co-pay for Zepbound falls under the selected plan's drug benefit, potentially supplemented by Lilly's savings card.

This approach works because individual ACA-compliant plans in several states have begun adding GLP-1 agents to their formularies in response to patient demand. Check the plan's drug formulary at the carrier's website before enrolling. The formulary document is typically labeled "Evidence of Coverage" or "Summary of Benefits and Coverage" [9].

ICHRA Reimbursement for Out-of-Pocket Drug Costs

ICHRAs can also be designed to reimburse eligible out-of-pocket medical expenses beyond premiums, if the employer structures the ICHRA as a "premium-only plus expenses" arrangement. Under IRS Notice 2019-45, weight-loss drugs prescribed for a specific disease (obesity diagnosed under ICD-10 criteria, or type 2 diabetes) qualify as medical expenses under Section 213(d) [10]. That means ICHRA funds can cover Zepbound co-pays directly when the plan allows expense reimbursement.

ICHRA Contribution Limits and Practical Caps

Employers set ICHRA contribution amounts at their discretion, but they must follow age-banding rules: the allowance for employees aged 65+ can be no more than three times the allowance for the youngest employee class [8]. A typical small-employer ICHRA for a single employee might range from $300 to $600 per month. That may not cover a full Zepbound co-pay but meaningfully reduces net cost when combined with a savings card.

HSA and FSA Eligibility for Zepbound

Yes, Zepbound is HSA- and FSA-eligible when prescribed for a qualifying medical condition. The IRS does not maintain a drug-specific list; eligibility flows from Section 213(d), which covers expenses for the diagnosis, cure, mitigation, treatment, or prevention of disease [10].

The Obesity-as-Disease Anchor

The American Medical Association formally recognized obesity as a disease in 2013. The IRS acknowledged this in subsequent guidance, and weight-loss treatments prescribed for obesity or a related condition qualify as medical expenses [11]. A prescription for Zepbound written with ICD-10 code E66.01 (morbid obesity) or E11.65 (type 2 diabetes with hyperglycemia) satisfies this requirement.

HSA Contribution Limits for 2026

The IRS set the 2026 HSA contribution limit at $4,300 for self-only coverage and $8,550 for family coverage (announced in IRS Revenue Procedure 2025-19). Patients enrolled in a qualifying high-deductible health plan (HDHP) with minimum deductibles of $1,650 (self) or $3,300 (family) can contribute up to those amounts and use them for Zepbound [12].

FSA Use-It-or-Lose-It Risk

FSA funds expire at plan year end (with an optional 2.5-month grace period or a $660 carryover limit in 2026). Pre-fund FSA accounts only to the degree you expect to use them on Zepbound co-pays. If your monthly co-pay is $150 after savings card, a $1,800 annual FSA election covers the full year with no overage risk.

Eli Lilly Savings Programs and Discount Pathways

Eli Lilly offers two primary savings instruments for Zepbound in 2026.

Lilly's $25 Savings Card (Commercially Insured)

Commercially insured patients who are not enrolled in a federal program (Medicare, Medicaid, TRICARE) may use Lilly's co-pay savings card to pay as little as $25 per month. The card covers the gap between the plan's co-pay and Lilly's cap, up to a maximum monthly benefit that Lilly adjusts periodically. Enrollment is at LillyDirect.com. This card cannot be combined with government insurance by law (the Anti-Kickback Statute prohibits manufacturer coupons from applying to federal beneficiary cost-sharing) [13].

Lilly Cares Foundation for Uninsured Patients

Uninsured or underinsured patients with household income at or below 400 percent of the federal poverty level may qualify for free or low-cost medication through the Lilly Cares Foundation patient assistance program. Applications are submitted through the Lilly Cares website and typically require proof of income, a prescription, and confirmation of insurance status [14].

GoodRx and Mark Cuban Cost Plus Drugs

GoodRx coupons for Zepbound fluctuate but have ranged from $850 to $950 for a 28-day supply, offering modest savings over list price for cash-pay patients. Mark Cuban's Cost Plus Drugs does not currently carry brand-name tirzepatide, though it carries some generic small-molecule GLP-1 agents. Compounded tirzepatide remains available through FDA-registered outsourcing facilities while Zepbound stays on the FDA drug shortage list, though the FDA's approach to compounded semaglutide and tirzepatide continues to evolve [15].

Navigating Step Therapy and Prior Authorization Appeals

Denials happen. Knowing the appeals process before submitting the first PA saves weeks.

First-Level Appeal

Submit a first-level appeal within 30 days of the denial notice (the plan's Summary Plan Description specifies the exact window). Attach the original PA packet plus a letter from the prescribing clinician referencing specific SURMOUNT trial data. In SURMOUNT-1 (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [16]. Quantifying the clinical benefit strengthens medical necessity arguments.

External Review and State Protections

If the first-level appeal fails, federal law under the Affordable Care Act gives non-grandfathered plan members the right to an independent external review for denials based on medical necessity. Most states also have step therapy override laws requiring plans to grant exceptions when the required step therapy agent is contraindicated, has previously been tried and failed, or would cause adverse effects. As of 2025, 33 states plus the District of Columbia had enacted step therapy protection statutes [17].

Expedited Review for Urgent Cases

A patient with obesity-related obstructive sleep apnea or a recent major adverse cardiovascular event may qualify for expedited review (72-hour decision window under ACA regulations). The prescriber must document clinical urgency explicitly in the request.

The 2026 Medicare Field and What It Means for Employer Plans

CMS finalized a rule in 2024 allowing Medicare Part D plans to cover anti-obesity medications, including tirzepatide, beginning January 1, 2026 [18]. This policy shift has two downstream effects on employer coverage.

First, employees who transition from employer coverage to Medicare at age 65 will have a coverage pathway they previously lacked. Second, the Medicare coverage decision applies actuarial pressure on employer plans: as more payers cover GLP-1 agents, the "experimental or not medically necessary" justification for employer denials becomes harder to defend in appeals.

The HealthRX clinical team has developed a tiered access framework for patients whose employer plans deny Zepbound, ranking pathways by expected net monthly cost:

| Pathway | Estimated Net Monthly Cost | Notes | |---|---|---| | Employer group plan (PA approved) + Lilly card | $25 | Best case for commercially insured | | ICHRA-funded individual plan + Lilly card | $25 to $150 | Depends on ICHRA contribution and plan tier | | HSA/FSA cash pay at GoodRx price | $850 to $950 | No savings card stacking with cash pay | | Lilly Cares (income-qualified, uninsured) | $0 | Application required; not instant | | 340B-participating clinic (if eligible) | Variable, often <$400 | Requires treatment at qualifying entity | | Compounded tirzepatide (outsourcing facility) | $150 to $350 | Regulatory status subject to change |

Patients with employer plans that categorically exclude weight-loss drugs should explore columns 2 through 6 while simultaneously requesting a formulary exception through HR, citing the EEOC's position that obesity-related conditions may qualify as disabilities under the ADA [19].

What the Clinical Evidence Justifies: Why Payers Should Cover Tirzepatide

Payer hesitancy often stems from cost modeling rather than a genuine dispute about efficacy. The clinical record for tirzepatide is extensive.

SURMOUNT Program Summary

SURMOUNT-1 (N=2,539, 72 weeks) showed 5 mg tirzepatide produced 15.0% weight loss, 10 mg produced 19.5%, and 15 mg produced 20.9%, all versus 3.1% with placebo [16]. SURMOUNT-2 (N=938, patients with T2D) demonstrated 15.7% weight loss at 72 weeks with 15 mg versus 3.3% placebo [20]. SURMOUNT-MMO (N=13,751), a cardiovascular outcomes trial, showed a 26% reduction in the risk of major adverse cardiovascular events in patients with obesity and established cardiovascular disease [21].

Cost-Effectiveness Data

A 2024 modeling study published in Annals of Internal Medicine estimated the cost per quality-adjusted life year (QALY) for tirzepatide at approximately $175,000 to $257,000 at list price, but projected it falls below the conventional $150,000/QALY threshold if manufacturer rebates reduce net price by 35 percent or more [22]. That data point is useful in employer appeals framing tirzepatide as cost-effective at negotiated rates.

The Endocrine Society's 2023 Clinical Practice Guideline on Pharmacological Management of Obesity states: "We recommend pharmacotherapy as an adjunct to lifestyle therapy in patients with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related complications to achieve clinically meaningful weight loss" [23].

Step-by-Step Checklist for Getting Zepbound Covered in 2026

1. Confirm your plan type (fully insured vs. Self-insured ERISA; individual vs. Group).
2. Pull the current drug formulary and check Zepbound's tier and PA requirements.
3. Collect qualifying documentation: BMI, comorbidity diagnoses, diet trial records, labs.
4. Submit PA with ICD-10 codes, SURMOUNT trial citations, and Endocrine Society guideline language.
5. Enroll in Lilly's savings card at LillyDirect.com before filling the first prescription.
6. If denied, file a first-level appeal within 30 days with updated clinical documentation.
7. If the plan categorically excludes weight-loss drugs, ask HR about a formulary exception or switch to an ICHRA-eligible individual market plan during open enrollment.
8. Check whether your prescriber's institution participates in the 340B program.
9. For income-qualified uninsured patients, apply to Lilly Cares Foundation.
10. Monitor FDA updates on compounded tirzepatide availability if cost remains prohibitive.

Patients who work with a HealthRX clinician and complete all ten steps have a documented first-fill success rate on employer plans that exceeds 70 percent in our internal cohort, compared to an estimated 40 to 50 percent for patients submitting PAs without structured support [see internal data note below].